DRD4 is the dopamine D4 receptor gene and is associated with ADHD and novelty seeking behaviors. It has been proposed that novelty seeking is associated with impulsivity. Mice deficient for DRD4 have shown less behavioral responses to novelty. 5HT2A is the serotonin receptor gene. The serotonin 2A receptor gene has been associated with both hyper locomotion, ADHD, as well as impulsivity. Subjects with a particular polymorphism of the 5HT2A gene made more commission errors during a punishment-reward condition in a go/no-go task. HTR2B a serotonin receptor gene. CTNNA2 encodes for a brain-expressed α-catenin that has been associated with Excitement-Seeking in a genome-wide association study (GWAS) of 7860 individuals. Intervention
Interventions to impact impulsivity generally
While impulsivity can take on pathological forms (e.g. substance use disorder, ADHD), there are less severe, non-clinical forms of problematic impulsivity in many peoples daily lives. Research on the different facets of impulsivity can inform small interventions to change decision making and reduce impulsive behavior For example, changing cognitive representations of rewards (e.g. making long term rewards seem more concrete) and/or creating situations of "precommitment" (eliminating the option of changing ones mind later)  can reduce the preference for immediate reward seen in delay discounting. Brain training
Brain training interventions include laboratory-based interventions (e.g. training using tasks like go/no go) as well as community, family, and school based interventions that are ecologically valid (e.g. teaching techniques for regulating emotions or behaviors) and can be used with individuals with non-clinical levels of impulsivity.
Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. It is a combination of dorzolamide hydrochloride and timolol maleate. It may be used when a beta blocker, like timolol, is not sufficient alone. It is used as an eye drop.Common side effects include eye discomfort, eye redness, taste changes, and blurry vision. Serious side effects may include allergic reactions and heart failure. Use is not recommended in those with asthma, a sulfonamide allergy, or a slow heart rate. Dorzolamide is a carbonic anhydrase inhibitor and timolol is a beta blocker. Both work by decreasing the amount of aqueous humor made by the eye.The combination was approved for medical use in the United States in 1998. It is available as a generic medication. In 2019, it was the 207th most commonly prescribed medication in the United States, with more than 2 million prescriptions. Adverse effects
Common adverse effects include temporarily blurred vision, cloudy vision, double vision, temporary burning/stinging/itching of the eye, watery eyes, feeling as if something is in the eye, drooping eyelid, sensitivity to light, cough, flu symptoms, nausea, and stomach pain.More serious adverse effects include dizziness, slow or irregular heartbeat, muscle weakness, mental/mood changes, and coldness/numbness/pain in the hands or feet. Pharmacology
Dorzolamide is a human carboanydrase II inhibitor. Inhibition of carboanhydrase in the ciliary processes of the eye decreases aqueous humor secretion supposedly by decreasing the formation rate of bicarbonate ions. This results in reduction in both sodium and fluid transport.